Current Rheumatology Reports最新文献

Management of IgG4-Related Disease. igg4相关疾病的管理。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-05-07 DOI: 10.1007/s11926-026-01224-0

Gabriela Hernández-Molina, Brian Uriel Anaya-Macías, Eduardo Martín-Nares

{"title":"Management of IgG4-Related Disease.","authors":"Gabriela Hernández-Molina, Brian Uriel Anaya-Macías, Eduardo Martín-Nares","doi":"10.1007/s11926-026-01224-0","DOIUrl":"https://doi.org/10.1007/s11926-026-01224-0","url":null,"abstract":"Purpose of the review: IgG4-related disease (IgG4-RD) is a chronic immune-mediated fibroinflammatory condition characterized by tumefactive lesions in multiple organs. Although glucocorticoids remain the cornerstone of therapy, high relapse rates and treatment-related toxicity have prompted the development of steroid-sparing strategies and targeted therapies. This review summarizes current evidence on pharmacological and non-pharmacological management of IgG4-RD and proposes a practical treatment approach based on available data and clinical experience.Recent findings: Glucocorticoids continue to be the first-line therapy for remission induction, achieving high initial response rates; however, relapses are common, particularly after tapering or withdrawal. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as mycophenolate mofetil, leflunomide, azathioprine, and methotrexate, are frequently used as steroid-sparing agents, although comparative evidence remains limited. B-cell targeted therapies have emerged as key treatment options. Rituximab has demonstrated high efficacy as first-line therapy and in refractory or relapsing disease, and is widely used despite remaining off-label in most regions. More recently, the anti-CD19 monoclonal antibody inebilizumab became the first therapy approved for IgG4-RD following the MITIGATE trial, which showed reduced disease flares and increased rates of glucocorticoid-free remission. Additional emerging therapies include obinutuzumab, obexelimab, CAR-T cell therapy, and cytokine-targeted agents such as dupilumab and tocilizumab, although evidence for most remains limited. Management of IgG4-RD requires an individualized approach based on disease severity, organ involvement, relapse risk, patient's comorbidities and preferences, and access to therapies. B-cell-directed therapies and other targeted agents are emerging as key components of treatment and may enable more effective and steroid-sparing disease control.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Care of the Patient with Interstitial Lung Disease Perioperatively. 间质性肺疾病患者围手术期的护理。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-04-30 DOI: 10.1007/s11926-026-01223-1

Kristin Berger, Genna Braverman, Aldis Siltumens, Jessica Gordon, Robert Kaner

引用次数: 0

Treat-to-Target Urate-lowering Therapy: Lessons Learned from the STOP Gout Study. 从治疗到目标尿酸降低疗法：从停止痛风研究中获得的经验教训。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-04-27 DOI: 10.1007/s11926-026-01220-4

Ted R Mikuls, Lindsay Helget, Jeff Newcomb, Austin Wheeler, James R O'Dell

引用次数: 0

Myositis Mimics: Recognizing Red Flags and Diagnostic Pitfalls. 肌炎模拟：识别危险信号和诊断陷阱。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-04-15 DOI: 10.1007/s11926-026-01219-x

Bhaskar Roy, Latika Gupta, Teerin Liewluck

引用次数: 0

Management of Severe Behçet's Disease. 严重behaperet病的管理。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-03-31 DOI: 10.1007/s11926-026-01217-z

Kerem Abacar, Haner Direskeneli, Fatma Alibaz-Oner

引用次数: 0

Behçet's Syndrome. 遗传病的综合症。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-03-24 DOI: 10.1007/s11926-026-01218-y

Yusuf Yazici, Gulen Hatemi

引用次数: 0

Is Gout an Autoinflammatory Disease? 痛风是一种自身炎症性疾病吗？

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-03-21 DOI: 10.1007/s11926-026-01216-0

Naomi Schlesinger, Dan Kaufmann

引用次数: 0

Management of Takayasu Arteritis - A 2026 Update. 高须动脉炎的管理- A 2026更新。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-03-20 DOI: 10.1007/s11926-026-01214-2

Tanaz A Kermani, Alessandro Tomelleri, Daniele Scaramuzzi, Swapnil Jagtap, Durga Prasanna Misra

{"title":"Management of Takayasu Arteritis - A 2026 Update.","authors":"Tanaz A Kermani, Alessandro Tomelleri, Daniele Scaramuzzi, Swapnil Jagtap, Durga Prasanna Misra","doi":"10.1007/s11926-026-01214-2","DOIUrl":"https://doi.org/10.1007/s11926-026-01214-2","url":null,"abstract":"Purpose of this review: Takayasu arteritis (TAK) is a chronic, large-vessel vasculitis disproportionately affecting young women. The consequences of vascular inflammation include stenotic and occlusive disease with resultant end organ ischemia and dysfunction impacting quality of life. In this review, we highlight the recent advances in the assessment of disease activity and damage and treatment of TAK.Recent findings: Distinguishing disease activity from vascular damage in patients with TAK is challenging. The PET Vascular Activity Score (PETVAS) and Vasculitis Activity using MR and PET Vasculitis Activity using MR and PET (VAMP) hold promise. Composite scores such as the TAK Integrated Disease Activity Index (TAIDAI) combine information from prevalent clinical features and FDG-PET. For damage assessment, the validation of the Large Vessel Vasculitis Index of Damage (LVVID) in patients with TAK and reports of serum biomarkers of fibrosis are important advances. The usual practice for treating patients with TAK is to combine glucocorticoids with DMARDs. Recent studies have shown the effectiveness of methotrexate or mycophenolate mofetil (alone or in combination), secukinumab, tofacitinib, and baricitinib while confirming the role of tumor necrosis factor alpha inhibitors or tocilizumab in the management of TAK. Vascular interventions are reserved for vascular damage or ischemia of major organs threatening their function or affecting the quality of life. Advances in the assessment of disease activity and damage using composite tools hold promise to improve the management of patients with TAK. More high-quality trials are required to better inform the evidence base for treating patients with TAK.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Emerging Therapeutics in Rheumatoid Arthritis. 修正：类风湿关节炎的新兴疗法。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-03-17 DOI: 10.1007/s11926-026-01215-1

Daniel J Carlson, Laura M Nichols, Larry W Moreland

引用次数: 0

Mechanistic Insights from Human Studies in Axial Spondyloarthritis: A T Cell Story. 轴性脊柱炎的人体研究机制：一个T细胞的故事。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2026-03-05 DOI: 10.1007/s11926-026-01213-3

Joy Um, Michael A Paley

引用次数: 0